
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) – Research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Mineralys Therapeutics in a research report issued on Thursday, November 5th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($4.56) for the year, down from their prior estimate of ($4.40). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.60) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2026 earnings at ($0.64) EPS and FY2027 earnings at ($2.35) EPS.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.09).
View Our Latest Stock Report on MLYS
Mineralys Therapeutics Price Performance
Shares of NASDAQ MLYS opened at $15.33 on Monday. The firm has a 50-day simple moving average of $23.78 and a 200-day simple moving average of $26.61. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -3.52 and a beta of 0.83. The company has a quick ratio of 11.83, a current ratio of 11.83 and a debt-to-equity ratio of 0.15. Mineralys Therapeutics has a 52 week low of $14.91 and a 52 week high of $47.65.
Institutional Investors Weigh In On Mineralys Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. ACT Capital Partners L.P. acquired a new position in Mineralys Therapeutics during the 3rd quarter worth about $2,196,000. Aberdeen Group plc grew its position in Mineralys Therapeutics by 29.8% in the 3rd quarter. Aberdeen Group plc now owns 894,403 shares of the company’s stock valued at $22,476,000 after acquiring an additional 205,168 shares in the last quarter. Ethic Inc. acquired a new position in Mineralys Therapeutics in the 3rd quarter valued at about $269,000. Alps Advisors Inc. increased its stake in Mineralys Therapeutics by 31.7% during the third quarter. Alps Advisors Inc. now owns 117,144 shares of the company’s stock worth $2,944,000 after purchasing an additional 28,168 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Mineralys Therapeutics during the third quarter worth about $114,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.
Insider Activity at Mineralys Therapeutics
In other Mineralys Therapeutics news, Director Daphne Karydas sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total value of $85,740.00. Following the sale, the director owned 6,200 shares of the company’s stock, valued at $177,196. The trade was a 32.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.46, for a total value of $1,909,500.00. Following the transaction, the chief executive officer owned 528,621 shares in the company, valued at $13,458,690.66. This trade represents a 12.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 197,195 shares of company stock worth $5,403,069. Company insiders own 18.94% of the company’s stock.
Mineralys Therapeutics Company Profile
Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company’s research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.
Mineralys’ lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.
Featured Articles
- Five stocks we like better than Mineralys Therapeutics
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
